Acumen Pharmaceuticals (ABOS) Competitors $1.18 -0.09 (-7.09%) Closing price 04:00 PM EasternExtended Trading$1.19 +0.01 (+1.19%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. AARD, MDWD, TVGN, ANNX, FHTX, SLRN, DSGN, URGN, CRDF, and CGCShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Aardvark Therapeutics (AARD), MediWound (MDWD), Tevogen Bio (TVGN), Annexon (ANNX), Foghorn Therapeutics (FHTX), Acelyrin (SLRN), Design Therapeutics (DSGN), UroGen Pharma (URGN), Cardiff Oncology (CRDF), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Aardvark Therapeutics MediWound Tevogen Bio Annexon Foghorn Therapeutics Acelyrin Design Therapeutics UroGen Pharma Cardiff Oncology Canopy Growth Aardvark Therapeutics (NASDAQ:AARD) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, community ranking, valuation and profitability. Do institutionals and insiders hold more shares of AARD or ABOS? 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has better valuation & earnings, AARD or ABOS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAardvark TherapeuticsN/AN/AN/AN/AN/AAcumen PharmaceuticalsN/AN/A-$52.37M-$1.94-0.61 Does the media refer more to AARD or ABOS? In the previous week, Aardvark Therapeutics had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Aardvark Therapeutics' score of 0.50 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Aardvark Therapeutics Positive Acumen Pharmaceuticals Positive Does the MarketBeat Community favor AARD or ABOS? Acumen Pharmaceuticals received 19 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Aardvark Therapeutics an outperform vote while only 71.05% of users gave Acumen Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAardvark TherapeuticsOutperform Votes880.00% Underperform Votes220.00% Acumen PharmaceuticalsOutperform Votes2771.05% Underperform Votes1128.95% Is AARD or ABOS more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aardvark TherapeuticsN/A N/A N/A Acumen Pharmaceuticals N/A -32.99%-27.99% Do analysts rate AARD or ABOS? Aardvark Therapeutics currently has a consensus price target of $31.25, suggesting a potential upside of 165.51%. Acumen Pharmaceuticals has a consensus price target of $7.33, suggesting a potential upside of 521.47%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryAcumen Pharmaceuticals beats Aardvark Therapeutics on 7 of the 12 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.48M$3.10B$5.57B$8.66BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-0.8633.8227.2020.17Price / SalesN/A476.37412.92161.90Price / CashN/A168.6838.2534.64Price / Book0.263.497.114.72Net Income-$52.37M-$72.35M$3.23B$247.80M7 Day Performance13.46%10.49%4.61%3.36%1 Month Performance20.40%24.23%13.35%9.71%1 Year Performance-54.96%-15.55%31.75%14.41% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals2.7979 of 5 stars$1.18-7.1%$7.33+521.5%-51.5%$71.48MN/A-0.8620Positive NewsAARDAardvark TherapeuticsN/A$11.13+6.6%$31.25+180.8%N/A$241.48MN/A0.0018Analyst RevisionGap UpMDWDMediWound1.9564 of 5 stars$22.24+1.3%$31.80+43.0%+25.9%$240.37M$19.21M-7.6780Positive NewsTVGNTevogen Bio4.0526 of 5 stars$1.29flat$7.10+450.4%+32.9%$237.22MN/A0.003Trending NewsAnalyst ForecastInsider TradeGap UpANNXAnnexon1.3424 of 5 stars$2.12+3.9%$12.50+489.6%-54.9%$232.59MN/A-2.0260FHTXFoghorn Therapeutics2.3071 of 5 stars$4.17+2.2%$12.13+190.8%-23.6%$232.44M$23.50M-2.17120Positive NewsSLRNAcelyrin2.9436 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135Positive NewsDSGNDesign Therapeutics0.5312 of 5 stars$4.02+7.8%$4.00-0.5%+1.6%$228.21MN/A-4.7340Positive NewsURGNUroGen Pharma4.2441 of 5 stars$4.84+14.2%$27.43+466.7%-46.9%$223.16M$91.87M-1.54200Trending NewsHigh Trading VolumeCRDFCardiff Oncology1.6692 of 5 stars$3.35-1.8%$12.00+258.2%+31.7%$222.86M$587,000.00-3.5620CGCCanopy Growth2.2815 of 5 stars$1.21-8.3%$2.00+65.3%-77.0%$222.48M$276.75M-0.323,150High Trading Volume Related Companies and Tools Related Companies AARD Competitors MDWD Competitors TVGN Competitors ANNX Competitors FHTX Competitors SLRN Competitors DSGN Competitors URGN Competitors CRDF Competitors CGC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
